Dickkopf-1 (DKK1), another WNT inhibitor, contributes to myeloma-related bone disease as the production of DKK1 by myeloma cells increases the RANKL/OPG ratio (Qiang et al., 2008). Here, TNFRSF11B is linked to plasma cell myeloma.